Rhapsido: payments to doctors
Payments that named Rhapsido as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $936K
- Providers
- 11,716
- Transactions
- 23,969
- Average per transaction
- $39
The per-transaction average — $39 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,716 providers the average total is $80, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $895,764 | 95.7% |
| Novartis Pharma AG | $40,086 | 4.3% |